Paper Details

  1. Home
  2. Paper Details

Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine.

Author: , BelaicheJ, BoitardJ, BonazB, CadiotG, CoffinB, ColombelJ-F, CortotA, FlouriéB, LémannM, MarteauP, MetmanE-H

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

TG is a possible alternative treatment in Crohn's disease patients, intolerant (especially for pancreatitis) or resistant to AZA/MP.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Tioguanine (TG) is an antimetabolite which may be regarded as an alternative to azathioprine (AZA)/mercaptopurine (MP) in patients with inflammatory bowel diseases. AIMS: : To evaluate the tolerance and efficacy of TG in patients with Crohn's disease, intolerant or resistant to AZA/MP. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2036.2003.01683.x

データ提供：米国国立医学図書館（NLM）

Tioguanine: A Potential Alternative for Crohn's Disease Treatment

Crohn's disease, a chronic inflammatory bowel disorder, can be a real challenge for patients. While [azathioprine (AZA) and mercaptopurine (MP)] are commonly used treatments, some individuals experience intolerance or resistance. This study investigated the effectiveness and safety of [tioguanine (TG)] as a potential alternative treatment option for those who don't respond well to AZA/MP.

Tioguanine: A Promising Treatment for Crohn's Disease

The study included [49 patients with Crohn's disease] who had either experienced intolerance or resistance to AZA/MP. The results showed that [TG was well-tolerated by most patients]. While some patients had to stop taking TG due to intolerance reactions, the majority experienced positive outcomes. The probability of clinical remission without [corticosteroids or infliximab] at 6 and 12 months was [46% and 79%, respectively]. This indicates that TG could offer a valuable alternative treatment option for individuals who struggle with traditional therapies.

Navigating Crohn's Disease Treatment: Considerations for Patients and Physicians

The findings of this study suggest that TG is a promising treatment option for individuals with Crohn's disease who are intolerant or resistant to AZA/MP. It's important to remember that each patient responds differently to treatments, and what works for one person may not work for another. It's essential to consult with a healthcare professional to discuss the potential benefits and risks of TG treatment.

Dr. Camel's Conclusion

This study offers hope for individuals with Crohn's disease struggling with treatment options. Tioguanine appears to be a viable alternative for those who have difficulty with traditional therapies. As a wise camel, I always emphasize the importance of personalized care and working closely with healthcare professionals to find the best treatment options for your specific needs. With perseverance and the right treatment, you can navigate the challenges of Crohn's disease and live a fulfilling life.

Date :
  1. Date Completed 2003-10-07
  2. Date Revised 2019-09-01
Further Info :

Pubmed ID

12940925

DOI: Digital Object Identifier

10.1046/j.1365-2036.2003.01683.x

Related Literature

Article Analysis
・Side Effects of thioguanine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.